NRSNW
OtherNeuroSense Therapeutics Ltd. Warrant
Live · NASDAQ · Mar 28, 6:08 AM
What's Moving NRSNW Today?
No AI insight has been generated for NRSNW yet. Check back soon — insights are generated from recent news analysis.
Generated Insights
No insights have been generated for NRSNW yet. Check back soon.
NRSNW News
15 articles- NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's ReadoutYahoo Finance·Mar 24, 2026
- /C O R R E C T I O N -- NeuroSense/Yahoo Finance·Mar 18, 2026
- NeuroSense to Host Investor Webinar on December 8, 2025Yahoo Finance·Nov 3, 2025
- NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease BiomarkersYahoo Finance·Oct 6, 2025
- Sector Update: Health Care Stocks Retreat Late AfternoonYahoo Finance·Sep 10, 2025
- NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived NeuronsYahoo Finance·Sep 10, 2025
- NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market PriceYahoo Finance·Sep 4, 2025
- NeuroSense Provides Business Update and Progress for the First Half of 2025Yahoo Finance·Aug 1, 2025
- Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and CommunityYahoo Finance·Jul 22, 2025
- Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst InsightsYahoo Finance·May 12, 2025
- NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market LaunchYahoo Finance·May 7, 2025
- NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership UpdateYahoo Finance·Apr 24, 2025
- NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS TreatmentYahoo Finance·Apr 9, 2025
- NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business UpdatesYahoo Finance·Apr 7, 2025
- NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology MeetingYahoo Finance·Apr 4, 2025
All 15 articles loaded
Price Data
52-Week Range
$0.20
Fundamentals
Trading
About NeuroSense Therapeutics Ltd. Warrant
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.